The potential of bioneedles to deliver influenza vaccines was investigated. Four influenza vaccine formulations were screened to determine the optimal formulation for use with bioneedles. The stability of the formulations after freeze-drying was checked to predict the stability of the influenza vaccines in the bioneedles. Subunit, split, virosomal and whole inactivated influenza (WIV) vaccine were formulated and lyophilized in bioneedles, and subsequently administered to C57BL/6 mice. Humoral and cellular immune responses were assessed after vaccination. The thermostability of lyophilized vaccines was determined after one-month storage at elevated temperatures. Bioneedle influenza vaccines induced HI titers that are comparable to those induced by intramuscular WIV vaccination. Delivery by bioneedles did not alter the type of immune response induced by the influenza vaccines. Stability studies showed that lyophilized influenza vaccines have superior thermostability compared to conventional liquid vaccines, and remained stable after one-month storage at 60°C. Influenza vaccines delivered by bioneedles are a viable alternative to conventional liquid influenza vaccines. WIV was determined to be the most potent vaccine formulation for administration by bioneedles. Lyophilized influenza vaccines in bioneedles are independent of a cold-chain, due to their increased thermostability, which makes distribution and stockpiling easier.
References
[1]
Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, et al. (2012) Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine 30: 4807–4812. doi: 10.1016/j.vaccine.2012.05.011
Mitragotri S (2006) Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 5: 543–548. doi: 10.1038/nrd2076
[4]
Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P, et al. (2003) Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21: 2830–2836. doi: 10.1016/s0264-410x(03)00175-0
[5]
de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL (1997) A pandemic warning? Nature 389: 554. doi: 10.1038/39218
[6]
Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931–939. doi: 10.1038/nature08157
[7]
Gao R, Cao B, Hu Y, Feng Z, Wang D, et al. (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888–1897. doi: 10.1056/nejmoa1304459
[8]
Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, et al. (2008) Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26: 6555–6563. doi: 10.1016/j.vaccine.2008.09.057
[9]
van de Wijdeven GG (2002) Development and assessment of mini projectiles as drug carriers. J Control Release 85: 145–162. doi: 10.1016/s0168-3659(02)00283-3
[10]
Hirschberg HJ, van de Wijdeven GG, Kelder AB, van den Dobbelsteen GP, Kersten GF (2008) Bioneedles as vaccine carriers. Vaccine 26: 2389–2397. doi: 10.1016/j.vaccine.2008.02.067
[11]
Hirschberg HJ, van de Wijdeven GG, Kraan H, Amorij JP, Kersten GF (2010) Bioneedles as alternative delivery system for hepatitis B vaccine. J Control Release 147: 211–217. doi: 10.1016/j.jconrel.2010.06.028
[12]
Budowsky EI, Friedman EA, Zheleznova NV, Noskov FS (1991) Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 9: 398–402. doi: 10.1016/0264-410x(91)90125-p
[13]
de Jonge J, Schoen P, ter Veer W, Stegmann T, Wilschut J, et al. (2006) Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim Biophys Acta 1758: 527–536. doi: 10.1016/j.bbamem.2006.03.011
[14]
Kapteyn JC, Porre AM, de Rond EJP, Hessels WB, Tijms MA, et al. (2009) HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 27: 1468–1477. doi: 10.1016/j.vaccine.2008.11.113
[15]
Estmer Nilsson C, Abbas S, Bennemo M, Larsson A, H？m？l？inen MD, et al. (2010) A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 28: 759–766. doi: 10.1016/j.vaccine.2009.10.070
[16]
Martin RM, Brady JL, Lew AM (1998) The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212: 187–192. doi: 10.1016/s0022-1759(98)00015-5
[17]
Choi HJ, Bondy BJ, Yoo DG, Compans RW, Kang SM, et al. (2013) Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release 166: 159–171. doi: 10.1016/j.jconrel.2012.12.002
[18]
Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, et al. (2008) Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses 2: 41–51. doi: 10.1111/j.1750-2659.2008.00038.x
[19]
Committee for Medicinal Products for Human Use (CHMP), Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. (CHMP/BWP/214/96).
[20]
Hillaire ML, Osterhaus AD, Rimmelzwaan GF (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011: 939860. doi: 10.1155/2011/939860
[21]
Goodwin K, Viboud C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159–1169. doi: 10.1016/j.vaccine.2005.08.105
[22]
Bodewes R, Kreijtz JH, Hillaire ML, Geelhoed-Mieras MM, Fouchier RA, et al. (2010) Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 91: 1743–1753. doi: 10.1099/vir.0.020784-0
[23]
Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, et al. (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 4: e1000138. doi: 10.1371/journal.ppat.1000138
[24]
Budimir N, de Haan A, Meijerhof T, Waijer S, Boon L, et al. (2013) Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine. PLoS One 8: e63163. doi: 10.1371/journal.pone.0063163
[25]
Amorij JP, Meulenaar J, Hinrichs WL, Stegmann T, Huckriede A, et al. (2007) Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25: 6447–6457. doi: 10.1016/j.vaccine.2007.06.054
[26]
Geeraedts F, Saluja V, ter Veer W, Amorij JP, Frijlink HW, et al. (2010) Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J 12: 215–222. doi: 10.1208/s12248-010-9179-z
[27]
de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, et al. (2007) Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci 32: 33–44. doi: 10.1016/j.ejps.2007.05.112
[28]
Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL (2008) Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 25: 1256–1273. doi: 10.1007/s11095-008-9559-6
